These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21890624)

  • 1. Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation.
    Liu XS; Song B; Elzey BD; Ratliff TL; Konieczny SF; Cheng L; Ahmad N; Liu X
    J Biol Chem; 2011 Oct; 286(41):35795-35800. PubMed ID: 21890624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development.
    Luo J; Liu X
    Protein Cell; 2012 Mar; 3(3):182-97. PubMed ID: 22447658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plk1 protein phosphorylates phosphatase and tensin homolog (PTEN) and regulates its mitotic activity during the cell cycle.
    Choi BH; Pagano M; Dai W
    J Biol Chem; 2014 May; 289(20):14066-74. PubMed ID: 24706748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
    Reagan-Shaw S; Ahmad N
    FASEB J; 2005 Apr; 19(6):611-3. PubMed ID: 15661849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phospho PTEN mediated dephosphorylation of mitotic kinase PLK1 and Aurora Kinase A prevents aneuploidy and preserves genomic stability.
    Ghosh G; Misra S; Ray R; Chowdhury SG; Karmakar P
    Med Oncol; 2023 Mar; 40(4):119. PubMed ID: 36930246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN regulates PLK1 and controls chromosomal stability during cell division.
    Zhang Z; Hou SQ; He J; Gu T; Yin Y; Shen WH
    Cell Cycle; 2016 Sep; 15(18):2476-85. PubMed ID: 27398835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state.
    Li Z; Li J; Bi P; Lu Y; Burcham G; Elzey BD; Ratliff T; Konieczny SF; Ahmad N; Kuang S; Liu X
    Mol Cell Biol; 2014 Oct; 34(19):3642-61. PubMed ID: 25047839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.
    Li J; Karki A; Hodges KB; Ahmad N; Zoubeidi A; Strebhardt K; Ratliff TL; Konieczny SF; Liu X
    Mol Cell Biol; 2015 Dec; 35(24):4185-98. PubMed ID: 26438599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?
    de Cárcer G
    Genes (Basel); 2019 Mar; 10(3):. PubMed ID: 30862113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.
    Shao C; Ahmad N; Hodges K; Kuang S; Ratliff T; Liu X
    J Biol Chem; 2015 Jan; 290(4):2024-33. PubMed ID: 25505174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polo-like kinase 1 is essential for early embryonic development and tumor suppression.
    Lu LY; Wood JL; Minter-Dykhouse K; Ye L; Saunders TL; Yu X; Chen J
    Mol Cell Biol; 2008 Nov; 28(22):6870-6. PubMed ID: 18794363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polo-like kinase 1 regulates mitotic arrest after UV irradiation through dephosphorylation of p53 and inducing p53 degradation.
    Chen J; Dai G; Wang YQ; Wang S; Pan FY; Xue B; Zhao DH; Li CJ
    FEBS Lett; 2006 Jun; 580(15):3624-30. PubMed ID: 16753148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals.
    Guan R; Tapang P; Leverson JD; Albert D; Giranda VL; Luo Y
    Cancer Res; 2005 Apr; 65(7):2698-704. PubMed ID: 15805268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic relevance of the protein phosphatase 2A in cancer.
    Cunningham CE; Li S; Vizeacoumar FS; Bhanumathy KK; Lee JS; Parameswaran S; Furber L; Abuhussein O; Paul JM; McDonald M; Templeton SD; Shukla H; El Zawily AM; Boyd F; Alli N; Mousseau DD; Geyer R; Bonham K; Anderson DH; Yan J; Yu-Lee LY; Weaver BA; Uppalapati M; Ruppin E; Sablina A; Freywald A; Vizeacoumar FJ
    Oncotarget; 2016 Sep; 7(38):61544-61561. PubMed ID: 27557495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
    Lin YC; Sun SH; Wang FF
    Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
    Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
    Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normal cells, but not cancer cells, survive severe Plk1 depletion.
    Liu X; Lei M; Erikson RL
    Mol Cell Biol; 2006 Mar; 26(6):2093-108. PubMed ID: 16507989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
    Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice.
    Guertin DA; Stevens DM; Saitoh M; Kinkel S; Crosby K; Sheen JH; Mullholland DJ; Magnuson MA; Wu H; Sabatini DM
    Cancer Cell; 2009 Feb; 15(2):148-59. PubMed ID: 19185849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer.
    Ito T; Sato F; Kan T; Cheng Y; David S; Agarwal R; Paun BC; Jin Z; Olaru AV; Hamilton JP; Selaru FM; Yang J; Matsumura N; Shimizu K; Abraham JM; Shimada Y; Mori Y; Meltzer SJ
    Int J Cancer; 2011 Nov; 129(9):2134-46. PubMed ID: 21170987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.